Other Events
Show detailsHide details
8.01 Other Events · 9.01 Financial Statements and Exhibits
Zentalis Pharmaceuticals, Inc.
A clinical-stage biopharmaceutical company developing small-molecule treatments for cancer, Zentalis focuses on targeted therapies for solid tumors. Its lead drug candidate, azenosertib (ZN-c3), is a WEE1 inhibitor designed to block a protein that helps cancer cells repair damaged DNA. The company is headquartered in San Diego, California.
8.01 Other Events · 9.01 Financial Statements and Exhibits
2.02 Results of Operations and Financial Condition · 7.01 Regulation FD Disclosure
5.07 Submission of Matters to a Vote of Security Holders
5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
7.01 Regulation FD Disclosure · 8.01 Other Events
2.02 Results of Operations and Financial Condition · 7.01 Regulation FD Disclosure
7.01 Regulation FD Disclosure · 8.01 Other Events
7.01 Regulation FD Disclosure